We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMadisen Joachim
Modified over 2 years ago
1 © 2004 TMIT TMIT 1 Value: Effective anti-coagulation management will be increasingly important to acute care hospital leaders. It is a key service tied to new Pay-For-Performance (P-4-P)programs, a therapy growing with our aging patient base, and one of the most frequent drugs involved in malpractice cases. There are new drugs on the horizon complicating the issue, however there are solutions that can help hospitals take an organized approach to this area. Evidence: Who benefits from such a program? The growing number of patients that are inadequately managed due to a lack of a systematic process who face disastrous consequences of preventable GI bleeding, CNS bleeding, and strokes due to clotting. Hospitals seeking to achieve the top tier performance in P-4-P: Payer programs such as the NQF Safe Practices initiative of the Leapfrog Group have identified this area as a high priority. It requires that hospitals have a systematic anticoagulation management program. What….are the key new solutions: Systematic anticoagulation Management (SAM). Originally developed through the Premier Innovation Institute, SAM has four elements: Management by qualified professional, scheduling and tracking, frequent accurate testing, and patient specific support and education. WebINR is a virtual anti-coagulation clinic, providing a web-based system for patients and physicians. Data is made available to physicians to monitor patient’s INR and provide decision support. WebINR also provides patient tracking, performance reports and patient education material at a low cost. It has demonstrated improvements of “in-range” INR values and reduced morbidity and mortality with patients. New Drug Exanta TM (Ximelagatran) is a potential replacement which does more required the same monitoring as warfarin. However, recent review by the FDA advisory panel indicates significant delay in its release. Furthermore, it is not indicated for heart valve patients which represent 1/3 of anti-coagulated patients. Where and when has this solution worked at frontline hospitals? Loma Linda VAMC has obtained great results using SAM with both reference lab and point of care testing devices – Preceptorship has been established and is open to all. El Camino Hospital – a 300 bed community hospital - has successfully implemented WebINR to monitor their patients with minimal investment Message: Why act now…why not wait…what if we pass? Act Now: In addition to preventing adverse events, and law suits a hospital has a robust anticoagulation clinic whereby a majority of the appropriate patients are managed after discharge, they will be prepared to meet future quality and P4P standards. There is still time to establish a program and receive recognition from payers and quality organizations. Wait: While certain evidence suggests that anticoagulation monitoring will not be necessary with new drugs such Exanta TM, another form of monitoring for liver enzyme levels may be required and will have to be addressed in a similar way. Hospitals that do not coordinate anticoagulation management will be at increased risk of litigation as such systematic management becomes standard of care. Pass: As time passes the risk will grow and it will be difficult for hospitals to catch up. If a competitor acts first you lose the lead role. Offering: How…..can a hospital get started? Contacts: Dr. Alan Jacobson (For Systematic Anti-coag Manag’t course) Ph 909-422-3097 email@example.com Jerry L. Pettis V.A. Medical Centerakjacobson@linkline.com Franck Guilloteau, CTO TMIT Ph.512-482-8888 Franck_Guilloteau@tmit1.org Resources: SAM Preceptorship – two day course at $300/person – contact Dr. Jacobson at firstname.lastname@example.org@linkline.com The Anticoagulation Forum (ACF) is a network of anticoagulation experts who work together to ensure safe and effective antithrombotic therapy for patients all over the country. The Anticoagulation Therapy Management Certificate Program is a six- week, 40-hour course taught five to six times per year at the University of Southern Indiana School of Nursing and Health Professions Web Sites: www.tmit1.org/PremierCEOSolutions www.acforum.orgwww.acforum.org - Anticoagulation Forum www.webinr.comwww.webinr.com – WebINR service http://health.usi.edu/anticoag/http://health.usi.edu/anticoag/ - Online Anticoagulation Therapy Management Certificate Program The CEO Solutions Series: Actionable Solutions for Senior Leaders Anti-coagulation Clinics: New Drivers – New Solutions
2 © 2004 TMIT TMIT Anticoagulation Clinics: New Drivers – New Solutions The CEO Solutions Series: Actionable Solutions for Senior Leaders
3 © 2004 TMIT TMIT Evidence Anticoagulation Management Services Anticoagulation therapy can reduce the risk for stroke by approximately 68%* Only 15% to 44% are prescribed warfarin* High impact – Strokes and Bleeds Warfarin Highly Litigated Drug New Drugs may confuse landscape *Source: Archives of Internal Medicine, 2000
4 © 2004 TMIT TMIT Evidence Payer Focus Service part of top tier requirement for Leapfrog NQF Safe Practices Leap Safe Practice with 4 th Highest Point Score in Survey 39/1000
5 © 2004 TMIT TMIT New Key Solutions…? Systematic Anticoagulation Management (SAM) Proven and Simple Minimal Hardware, software investment WebINR Bringing Patients and Physician Together New Drug Solutions Ximelagatran - Exanta TM
6 © 2004 TMIT TMIT Ongoing Patient Education Ongoing QI Direct Active Management by Qualified Health Care Provider Patient Scheduling and Tracking Accessible, Accurate, and Frequent PT/INR Testing Patient-specific Decision Support and Interaction Systematic Anticoagulation Management (SAM)
7 © 2004 TMIT TMIT WebINR Low Cost Web Based application Enables SAM – Tracking Patient, Decision Support and Education
8 © 2004 TMIT TMIT New Drug Exanta TM (Ximelagatran) Potential Warfarin Replacement with no Diet Restriction… However; Not indicated for Heart Valve Patients Recent FDA Advisory Panel vote Against release without further studies
9 © 2004 TMIT TMIT Anticoagulation Services Act Now: Minimal Investment and Great Outreach Program to the Community Meet future quality and P4P standards Delayed Action: Increased risk of lawsuits as systematic monitoring becomes standard of care. New Drugs such Exanta TM will still require some monitoring process Pass: Hospital cannot afford to “pass” - it is core to patient safety and providing quality care.
The role of Informatics in Patient Safety Dr. Sukhen Dey Indianan University Southeast.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
HM Modern Hospital Administrator The content 1.Ideal hospital CEO 2.Issues faced by Modern Hospital Administrator.
‘Preventing and treating blood clots’ The South Tees Anticoagulation Team 1.
Performance Measurement Orientation To schedule a presentation of “Performance Measurement Orientation” for your organization staff and/or collaborators,
by Joint Commission International (JCI)
FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.
MEDICAL HOME 1/2009 Mary Goldman, D.O., President of MAOFP.
Older People with Dementia in Acute Care: K ey messages from the NAO report Paul Forte The Balance of Care Group
1 © 2004 TMIT TMIT The Leapfrog NQF Safe Practices Briefing Carol Ferguson, RN, MSN Director of Patient Safety and Performance Improvement Texas Medical.
South Tees Hospitals Hospital Discharge Bev Walker Assistant Director of Nursing and Patient Safety Patients are central to everything we do.
My Mom’s Legacy Our Mission Prevent medical errors by ensuring that patients and families have the KNOWLEDGE they need to promote a safe hospital experience.
Evolution of Clinical Psychology
Using drug use evaluation (DUE) to optimise analgesic prescribing in emergency departments (EDs) Karen Kaye, Susie Welch. NSW Therapeutic Advisory Group*
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
September 10, 2008 Medication Safety: Anticoagulation Management Carla S. Huber, ARNP MS Community Anticoagulation Therapy (CAT) Clinic Cedar Rapids, IA.
CCHSA Accreditation: New Standards for Managing Medications
Chronic Medication Service (CMS). Programme Introduction Pharmaceutical Care Planning - Ray ePharmacy Programme – Dawn, IM & T Workshops – Niall, Michelle,
Transforming Community Services Commissioning Information for Community Services Stakeholder Workshop 14 October 2009 Coleen Milligan – Project Manager.
Local Enhanced Service Care bundles Dr Andy Kilpatrick, Clinical Lead.
© 2017 SlidePlayer.com Inc. All rights reserved.